ABIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ARCA biopharma's quarterly accounts payable & accrued expense declined from Sep. 2023 ($0.90 Mil) to Dec. 2023 ($0.54 Mil) but then increased from Dec. 2023 ($0.54 Mil) to Mar. 2024 ($1.50 Mil).
ARCA biopharma's annual accounts payable & accrued expense declined from Dec. 2021 ($2.57 Mil) to Dec. 2022 ($0.96 Mil) and declined from Dec. 2022 ($0.96 Mil) to Dec. 2023 ($0.54 Mil).
The historical data trend for ARCA biopharma's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 0.80 | 2.68 | 2.57 | 0.96 | 0.54 |
ARCA biopharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 1.03 | 1.41 | 0.90 | 0.54 | 1.50 |
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
James P Flynn | director | 41 HARRIS CT, DANVILLE CA 94526 |
Funicular Funds, Lp | 10 percent owner, other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Funicular Fund, Lp | other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Jacob Ma-weaver | other: See Remarks | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Christopher David Ozeroff | officer: S.V.P., General Counsel | 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021 |
Robert E Conway | director | C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
C. Jeffrey Dekker | officer: Chief Financial Officer | 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021 |
Thomas A Keuer | officer: Chief Operating Officer | C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021 |
Brian L. Selby | officer: VP, Finance | 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020 |
Venrock Healthcare Capital Partners Lp | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Scott D Sandell | 10 percent owner | |
David M Mott | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Forest Baskett | 10 percent owner | |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-16-2022
By Marketwired Marketwired • 10-28-2021
By PurpleRose PurpleRose • 07-11-2022
By Don Li2 Don Li2 • 11-02-2021
By GuruFocusNews GuruFocusNews • 06-15-2022
By Marketwired Marketwired • 08-16-2021
By GuruFocusNews GuruFocusNews • 05-05-2022
By GuruFocusNews GuruFocusNews • 03-31-2022
By Value_Insider Value_Insider • 10-28-2022
By GuruFocusNews GuruFocusNews • 05-26-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.